The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Increased Expression of Cyclooxygenase-2 is Associated with the Progression to Cirrhosis

  • Jeong, Soung-Won (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine) ;
  • Jang, Jae-Young (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine) ;
  • Lee, Sae-Hwan (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine) ;
  • Kim, Sang-Gyun (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine) ;
  • Cheon, Young-Koog (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine) ;
  • Kim, Young-Seok (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine) ;
  • Cho, Young-Deok (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine) ;
  • Kim, Hong-Soo (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine) ;
  • Lee, Joon-Seong (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine) ;
  • Jin, So-Young (Department of Pathology, Soonchunhyang University College of Medicine) ;
  • Shim, Chan-Sup (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Kim, Boo-Sung (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine)
  • Received : 2009.12.04
  • Accepted : 2010.05.24
  • Published : 2010.12.01
⟨ Previous Next ⟩

Abstract

Background/Aims: To investigate the degree of cyclooxygenase-2 (COX-2) protein expression in chronic hepatitis and cirrhosis. Methods: COX-2 protein expression was evaluated in 43 cases of chronic hepatitis and 24 cases of cirrhosis using immunohistochemical techniques. The COX-2 immunohistochemical staining score was assessed using the scoring systems of Pazirandeh et al and Qiu et al. and each scoring system was based on a sum of the parameters of staining intensity and distribution. Results: The mean COX-2 expression scores in chronic hepatitis and cirrhosis were $2.5{\pm}1.3$ vs. $3.3{\pm}1.1$ (p = 0.008), and $3.2{\pm}2.0$ vs. $4.5{\pm}1.7$ (p = 0.006), respectively, based on the Pazirandeh et al. and Qiu et al. scoring systems. The percentage samples of high COX-2 expression score (4 to 5) in chronic hepatitis and cirrhosis were 16.3% vs. 45.8% (p = 0.022), and 23.3% vs. 50% (p = 0.021), respectively, based on the two scoring systems. The mean COX-2 expression scores based on the severity of hepatic fibrosis scored using Ishak's modified staging system (fibrosis score 0 to 3 vs. 4 to 6) were $2.4{\pm}1.3$ vs. $3.2{\pm}1.1$ (p = 0.009), and $3.1{\pm}2.0$ vs. $4.3{\pm}1.8$ (p = 0.009), respectively, based on the two scoring systems. Conclusions: COX-2 expression was significantly higher in liver cirrhosis group than in chronic hepatitis. COX-2 expression scores according to Ishak's staging was significantly higher in the advanced fibrosis group. COX-2 may play a role in the progression of hepatic fibrosis.

Keywords

References

  1. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-7916. https://doi.org/10.1038/sj.onc.1203286
  2. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-3789.
  3. Dimberg J, Samuelsson A, Hugander A, Söderkvist P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999;45:730-732. https://doi.org/10.1136/gut.45.5.730
  4. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
  5. Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000;6:519-525.
  6. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-78. https://doi.org/10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G
  7. Ochiai M, Oguri T, Isobe T, Ishioka S, Yamakido M. Cyclooxygenase-2 $({COX-}_2)$ mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res 1999;90:1338-1343. https://doi.org/10.1111/j.1349-7006.1999.tb00717.x
  8. Agrawal A, Fentiman IS. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 2008;62:444-449. https://doi.org/10.1111/j.1742-1241.2007.01668.x
  9. Kondo M, Yamamoto H, Nagano H, et al. Increased expression of ${COX-}_2$ in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 1999;5:4005-4012.
  10. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999;29:688-696. https://doi.org/10.1002/hep.510290355
  11. Shiota G, Okubo M, Noumi T, et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999;46:407-412.
  12. Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase- 2 $({COX-}_2)$ in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a ${COX-}_2$ inhibitor, NS-398. Clin Cancer Res 2001;7:1410-1418.
  13. Radaeva S, Li Y, Hacker HJ, Burger V, Kopp-Schneider A, Bannasch P. Hepadnaviral hepatocarcinogenesis: in situ visualization of viral antigens, cytoplasmic compartmentation, enzymic patterns, and cellular proliferation in preneoplastic hepatocellular lineages in woodchucks. J Hepatol 2000;33:580-600. https://doi.org/10.1034/j.1600-0641.2000.033004580.x
  14. Huang SN, Chisari FV. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 1995;21:620-626.
  15. Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 1990;50:3400-3407.
  16. Ueno Y, Moriyama M, Uchida T, Arakawa Y. Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease. Hepatology 2001;33:357-362. https://doi.org/10.1053/jhep.2001.21902
  17. Hu KQ. Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 2002;139:234-243. https://doi.org/10.1067/mlc.2002.122281
  18. Cheng AS, Chan HL, Leung WK, et al. Expression of HBx and ${COX-}_2$ in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of ${COX-}_2$. Mod Pathol 2004;17:1169-1179. https://doi.org/10.1038/modpathol.3800196
  19. Pazirandeh S, Khettry U, Gordon FD, Resnick RH, Murray JE, Sheth SG. Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States. Dig Dis Sci 2007;52:220-227. https://doi.org/10.1007/s10620-006-9184-3
  20. Gallois C, Habib A, Tao J, et al. Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factoralpha in human hepatic stellate cells. Involvement of cyclooxygenase-2. J Biol Chem 1998;273:23183-23190. https://doi.org/10.1074/jbc.273.36.23183
  21. Mallat A, Gallois C, Tao J, et al. Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors. J Biol Chem 1998;273:27300-27305. https://doi.org/10.1074/jbc.273.42.27300
  22. Failli P, DeFranco RM, Caligiuri A, et al. Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology 2000;119:479-492. https://doi.org/10.1053/gast.2000.9354
  23. Hui AY, Leung WK, Chan HL, et al. Effect of celecoxib on experimental liver fibrosis in rat. Liver Int 2006;26:125-136. https://doi.org/10.1111/j.1478-3231.2005.01202.x
  24. Reilly TP, Brady JN, Marchick MR, et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol 2001;14:1620-1628. https://doi.org/10.1021/tx0155505
  25. Yu J, Wu CW, Chu ES, et al. Elucidation of the role of ${COX-}_2$ in liver fibrogenesis using transgenic mice. Biochem Biophys Res Commun 2008;372:571-577. https://doi.org/10.1016/j.bbrc.2008.05.069
  26. Yamamoto H, Kondo M, Nakamori S, et al. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1. Gastroenterology 2003;125:556-571. https://doi.org/10.1016/S0016-5085(03)00904-1
  27. Denda A, Endoh T, Kitayama W, et al. Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. Carcinogenesis 1997;18:1921-1930. https://doi.org/10.1093/carcin/18.10.1921
  28. Tu CT, Guo JS, Wang M, Wang JY. Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury. J Gastroenterol Hepatol 2007;22:877-884. https://doi.org/10.1111/j.1440-1746.2007.04867.x
  29. Planagumà A, Clària J, Miquel R, et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J 2005;19:1120-1122. https://doi.org/10.1096/fj.04-2753fje
  30. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699. https://doi.org/10.1016/0168-8278(95)80226-6
  31. Qiu DK, Ma X, Peng YS, Chen XY. Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma. World J Gastroenterol 2002;8:815-817. https://doi.org/10.3748/wjg.v8.i5.815
  32. Morinaga S, Yamamoto Y, Noguchi Y, et al. Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma. J Gastroenterol Hepatol 2002;17:1110-1116. https://doi.org/10.1046/j.1440-1746.2002.02836.x
  33. Cheng AS, Chan HL, Leung NW, et al. Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of antiviral therapy. Aliment Pharmacol Ther 2002;16:251-260. https://doi.org/10.1046/j.1365-2036.2002.01163.x
  34. Yu J, Hui AY, Chu ES, et al. Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis. Gut 2007;56:991-999. https://doi.org/10.1136/gut.2006.097923
  35. Vanchieri C. Vioxx withdrawal alarms cancer prevention researchers. J Natl Cancer Inst 2004;96:1734-1735. https://doi.org/10.1093/jnci/96.23.1734

Cited by

  1. Capsaicin induces de-differentiation of activated hepatic stellate cell vol.90, pp.6, 2012, https://doi.org/10.1139/o2012-026
  2. Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma vol.18, pp.3, 2010, https://doi.org/10.3350/cmh.2012.18.3.287
  3. Celecoxib, a selective cyclooxygenase-2 inhibitor, lowers plasma cholesterol and attenuates hepatic lipid peroxidation during carbon-tetrachloride-associated hepatotoxicity in rats vol.36, pp.1, 2013, https://doi.org/10.3109/01480545.2011.642380
  4. Increased circulating Lin−/lowCD33+HLA‐DR− myeloid‐derived suppressor cells in hepatocellular carcinoma patients vol.44, pp.6, 2010, https://doi.org/10.1111/hepr.12167
  5. Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial‐to‐mesenchymal transition of hepatocytes vol.29, pp.11, 2010, https://doi.org/10.1111/jgh.12641
  6. Fucoidan from Fucus vesiculosus Protects against Alcohol-Induced Liver Damage by Modulating Inflammatory Mediators in Mice and HepG2 Cells vol.13, pp.2, 2010, https://doi.org/10.3390/md13021051
  7. Cyclooxygenase-2 Inhibitor Reduces Hepatic Stiffness in Pediatric Chronic Liver Disease Patients Following Kasai Portoenterostomy vol.57, pp.4, 2010, https://doi.org/10.3349/ymj.2016.57.4.893
  8. Ligustrazine-Oleanolic Acid Glycine Derivative, G-TOA, Selectively Inhibited the Proliferation and Induced Apoptosis of Activated HSC-T6 Cells vol.21, pp.11, 2016, https://doi.org/10.3390/molecules21111599
  9. Expression of cyclooxygenase-2 is correlated with lncRNA-COX-2 in cirrhotic mice induced by carbon tetrachloride vol.15, pp.4, 2010, https://doi.org/10.3892/mmr.2017.6161
  10. The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD) vol.4, pp.3, 2010, https://doi.org/10.3390/ncrna4030018
  11. Anti-inflammatory and hepatoprotective effects of exopolysaccharides isolated from Pleurotus geesteranus on alcohol-induced liver injury vol.8, pp.None, 2010, https://doi.org/10.1038/s41598-018-28785-0
  12. Treatment with either COX‐2 inhibitor or 5‐LOX inhibitor causes no compensation between COX‐2 pathway and 5‐LOX pathway in chronic aluminum overload‐induced liver injury vol.33, pp.5, 2019, https://doi.org/10.1111/fcp.12465
  13. Celecoxib attenuates hepatocyte apoptosis by inhibiting endoplasmic reticulum stress in thioacetamide-induced cirrhotic rats vol.26, pp.28, 2010, https://doi.org/10.3748/wjg.v26.i28.4094
  14. Role of eicosanoids in liver repair, regeneration and cancer vol.192, pp.None, 2021, https://doi.org/10.1016/j.bcp.2021.114732